NCT01077648View on ClinicalTrials.gov

Brain Metastasis in Breast Cancer Patients

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Cancer
Interventions
DRUG

Trastuzumab or Lapatinib

Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01077648 - Brain Metastasis in Breast Cancer Patients | Biotech Hunter | Biotech Hunter